CoChat
Cited by 218

The DOI matches its OpenAlex record.

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.

Tadeusz Robak, Jerzy Z. Błoński, Marek Kasznicki, Maria Błasińska-Morawiec, Euzebiusz Krykowski, Anna Dmoszyńska, Halina Mrugala-Śpiewak, Aleksander B. Skotnicki, W Nowak, L Konopka, Bernadeta B. Ceglarek, Stanisław Maj, Jadwiga Dwilewicz‐Trojaczek, Andrzej Hellmann, Ignacy Urasiński, Barbara Zdziarska, Sabina Kotlarek-Haus, Stanislaw Potoczek, Paweł Grieb · 2000 · PubMed

Abstract

The efficacy and toxicity of cladribine (2-CdA) + prednisone (P) versus chlorambucil (Chl) + P were compared in previously untreated patients with progressive or symptomatic chronic lymphocytic leukemia (CLL) in a randomized, multicenter prospective trial. Eligible patients were assigned to either 2-CdA 0.12 mg/kg per day in 2-hour infusions and P 30 mg/m(2) per day for 5 consecutive days or Chl 12 mg/m(2) per day and P 30 mg/m(2) per day for 7 consecutive days. Three courses were administered at 28-day intervals or longer if myelosuppression developed. The therapy was finished if complete response (CR) was achieved. Of 229 available patients 126 received 2-CdA+P and 103 received Chl+P as a first-line treatment. CR and overall response rates were significantly higher in the patients treated with 2-CdA+P (47% and 87%, respectively) than in the patients treated with Chl+P (12% and 57%, respectively) (P = .001). Progression-free survival was significantly longer in the 2-CdA-treated group (P = .01), but event-free survival was not statistically different. Thirteen percent of patients were refractory to 2-CdA+P and 43% to Chl+P (P = .001). Drug-induced neutropenia was more frequently observed during 2-CdA+P (23%) than Chl+P therapy (11%) (P = .02), but thrombocytopenia occurred with similar frequency in both groups (36% and 27%, respectively). Infections were seen more frequently in the 2-CdA+P-treated group (56%) than in the Chl+P-treated group (40%; P = .02). Death rates have so far been similar in patients treated with 2-CdA (20%) and with Chl (17%). The probability of overall survival calculated from Kaplan-Meier curves at 24 months was also similar for both groups (78% and 82%, respectively). (Blood. 2000;96:2723-2729)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.1182/blood.v96.8.2723.h8002723_2723_2729

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 218

Metadata

Authors
Robak, T., Błoński, J. Z., Kasznicki, M., Błasińska-Morawiec, M., Krykowski, E., Dmoszyńska, A., Mrugala-Śpiewak, H., Skotnicki, A. B., Nowak, W., Konopka, L., Ceglarek, B. B., Maj, S., Dwilewicz‐Trojaczek, J., Hellmann, A., Urasiński, I., Zdziarska, B., Kotlarek-Haus, S., Potoczek, S., & Grieb, P.
Venue
PubMed
Publisher
National Institutes of Health
Published
2000-10-15
Volume
96
Issue
8
Pages
2723-9
OpenAlex
W1594668159
Cited by
218
References
0
FWCI
8.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. https://app.cochat.ai/papers/10.1182/blood.v96.8.2723.h8002723_2723_2729
The paper
Robak, T., Błoński, J. Z., Kasznicki, M., Błasińska-Morawiec, M., Krykowski, E., Dmoszyńska, A., Mrugala-Śpiewak, H., Skotnicki, A. B., Nowak, W., Konopka, L., Ceglarek, B. B., Maj, S., Dwilewicz‐Trojaczek, J., Hellmann, A., Urasiński, I., Zdziarska, B., Kotlarek-Haus, S., Potoczek, S., & Grieb, P. (2000). Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. PubMed. https://doi.org/10.1182/blood.v96.8.2723.h8002723_2723_2729

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.